Regulus Therapeutics (NASDAQ:RGLS) Receiving Somewhat Positive Press Coverage, Report Shows

Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regulus Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.8847528699432 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Regulus Therapeutics (NASDAQ RGLS) remained flat at $$0.89 during mid-day trading on Tuesday. 302,498 shares of the stock traded hands, compared to its average volume of 868,730. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. Regulus Therapeutics has a 1 year low of $0.79 and a 1 year high of $3.01.

Several equities analysts have commented on RGLS shares. Wedbush reaffirmed an “ourperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a research report on Monday, August 7th. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Saturday, September 16th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $2.60.

COPYRIGHT VIOLATION NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/regulus-therapeutics-rgls-earning-somewhat-favorable-media-coverage-report-shows.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply